Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 percent of their total body weight over the 72-week trial. SUBSCRIBE LOG IN ...

A five-year trial of the weight loss drug tirzepatide in Greater Manchester was announced last October ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Endocrinology > Obesity Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says — Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to ...

Diabetes drug Mounjaro helped people lose 16% of weight, study finds Two trials have now found tirzepatide, sold under the brand name Mounjaro as a diabetes treatment, to be effective for weight loss.

Eli Lilly's tirzepatide helped people lose up to 50 pounds, the sort of weight loss results only consistently seen with bariatric surgery. ... The trial was run in the U.S., Argentina, Brazil, ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.